10-Q: Gossamer Bio Reports Increased Losses Amid Seralutinib Trials

Gossamer Bio reported a significant increase in net loss for the nine months ended September 30, 2025, despite progress in its seralutinib clinical programs and ongoing collaboration revenue.

Summary

• Net loss for the nine months ended September 30, 2025, significantly increased to $123.1 million, compared to $23.5 million for the same period in 2024.
• Total revenue for the nine months decreased to $34.7 million in 2025 from $105.3 million in 2024, primarily due to a one-time license sale in the prior year.
• Research and development (R&D) expenses rose to $125.2 million for the nine months ended September 30, 2025, up from $102.4 million in 2024, driven by increased costs for seralutinib clinical trials.
• The company completed enrollment for the Phase 3 PROSERA Study in PAH patients in June 2025, with topline data expected in February 2026.
• The global registrational Phase 3 SERANATA Study for PH-ILD treatment activated its first clinical site in October 2025.
• Gossamer Bio entered into an option agreement to acquire Prana Bio, Inc. and its subsidiary Respira Therapeutics, Inc. on September 24, 2025, issuing 2,500,000 shares of common stock valued at $7.5 million as consideration.
• Cash, cash equivalents, and marketable securities totaled $180.2 million as of September 30, 2025, down from $294.5 million at December 31, 2024.
• Management believes existing capital is sufficient to fund operations through at least the next 12 months from the filing date.

Sentiment

Score: 4

Explanation: While clinical programs for seralutinib are progressing with key milestones achieved (PROSERA enrollment completion, SERANATA initiation) and a strategic collaboration with Chiesi is in place, the financial performance shows significant deterioration. The substantial increase in net loss and cash burn, coupled with the explicit need for future capital raises, indicates a challenging financial position and high operational risk. The Prana option adds a new program but also immediate IPR&D expense and future funding commitments.

Positives

• Revenue from contracts with collaborators increased to $13.3 million for the three months ended September 30, 2025, up from $9.5 million in the prior year period.
• Enrollment for the registrational Phase 3 PROSERA Study in PAH patients was completed in June 2025, a key development milestone.
• The global registrational Phase 3 SERANATA Study for PH-ILD treatment initiated its first clinical site in October 2025, expanding the seralutinib development pipeline.
• The strategic global partnership with Chiesi Farmaceutici S.p.A and Chiesi USA, Inc. provides ongoing cost-sharing for R&D and pre-commercial services, and potential future milestone payments and royalties.

Negatives

• Net loss significantly increased to $48.2 million for the three months ended September 30, 2025, compared to $30.8 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, surged to $123.1 million, a substantial increase from $23.5 million in the same period of 2024.
• Total revenue for the nine months ended September 30, 2025, decreased by $70.65 million to $34.7 million, primarily due to the absence of the $88.75 million revenue from sale of licenses recognized in 2024.
• Cash, cash equivalents, and marketable securities decreased to $180.2 million as of September 30, 2025, from $294.5 million at December 31, 2024, indicating significant cash burn.
• Operating activities used $123.0 million of cash during the nine months ended September 30, 2025, a sharp contrast to the $32.0 million provided in the prior year period.
• Accumulated deficit reached $1,391.7 million as of September 30, 2025, reflecting continued operating losses since inception.

Risks

• The company has incurred significant operating losses since inception and expects to continue to do so for the foreseeable future, with no assurance of future profitability.
• Additional capital will be required through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses, and similar arrangements, with no guarantee of success or sufficiency.
• Failure to raise additional capital when needed could force delays, limitations, reductions, or termination of seralutinib development or future commercialization efforts.
• The timing, duration, and completion costs of preclinical studies and clinical trials for seralutinib are inherently unpredictable, and actual development timelines and costs may differ materially from expectations.
• The company will incur significant commercialization expenses if seralutinib receives regulatory approval, and does not expect product sales revenue until successful development and approval, which is years away.
• Future capital raises through equity or convertible debt securities could dilute the ownership interest of existing stockholders.
• Debt financing and preferred equity financing may involve agreements with covenants that limit the company's ability to take specific actions.
• Raising funds through collaborations or licenses may require relinquishing valuable rights to technologies, future revenue streams, or product candidates.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future as it advances seralutinib through development and seeks regulatory approvals, including ongoing and planned clinical trials. Topline data from the Phase 3 PROSERA study in PAH is anticipated in February 2026. The company will need to raise additional capital through equity offerings, debt financings, or other arrangements to fund future operations beyond the next 12 months.

Management Comments

• Our goal is to be an industry leader in, and to enhance the lives of patients living with PH.
• We have assembled a deeply experienced and highly skilled group of industry veterans, scientists, clinicians and key opinion leaders from leading biotechnology and pharmaceutical companies, as well as leading academic centers from around the world.
• Our employees are a team of highly dedicated, passionate individuals who pride themselves on a culture of respect, humility, transparency, inclusion, dedication, collaboration and fun.
• Our ultimate goal is to enhance and extend the lives of patients.
• We expect to incur expenses and operating losses for the foreseeable future as we continue our development of and seek regulatory approvals for seralutinib.
• We do not expect to generate any revenue from product sales unless and until we successfully complete development and obtain regulatory approval for seralutinib, which we expect will take a number of years.
• Management believes that it has sufficient working capital on hand to fund operations through at least the next 12 months from the date these unaudited condensed consolidated financial statements were available to be issued.

Industry Context

Gossamer Bio operates in the highly specialized and capital-intensive biopharmaceutical sector, focusing on pulmonary hypertension (PH), including PAH and PH-ILD, which are severe and life-threatening conditions with significant unmet medical needs. The company's strategy involves late-stage clinical development of seralutinib, supported by a global collaboration with Chiesi, a move common in the industry to share high R&D costs and leverage commercial expertise. The recent option agreement to acquire Prana Bio and its RT234 program suggests a potential expansion of its pipeline within respiratory diseases, aligning with a trend of strategic acquisitions to diversify and strengthen product portfolios.

Legal Proceedings

• Not currently subject to any material legal proceedings.

Related Party Transactions

• The Chiesi Collaboration Agreement involves ongoing cost-sharing payments for research and development and pre-commercial services, and potential future milestone payments and royalties.
• An Equity Option was granted to Chiesi to purchase common stock, which was valued at $0.5 million and reduced the transaction price of the collaboration agreement.

Stakeholder Impact

• Shareholders face potential dilution from future equity or convertible debt financings, but also stand to benefit from successful clinical trial outcomes and regulatory approvals for seralutinib.
• Employees are engaged in critical R&D efforts, with job security tied to the company's ability to secure ongoing funding and achieve clinical success.
• Future patients with PH, PAH, and PH-ILD could benefit from seralutinib if it successfully completes clinical development and gains regulatory approval, offering a new therapeutic option.
• Creditors, particularly holders of the 2027 Notes, face risks associated with the company's ongoing losses and need for additional capital, as the notes are unsecured and effectively subordinated to secured indebtedness.

Next Steps

• Report topline data from the Phase 3 PROSERA study in PAH patients in February 2026.
• Continue the global registrational Phase 3 SERANATA Study for the treatment of PH-ILD.
• Continue development of seralutinib and seek regulatory approvals.
• Potentially exercise the option to acquire Prana Bio, Inc. and its subsidiary Respira Therapeutics, Inc.
• Raise additional capital to fund ongoing operations and development activities.

Key Dates

Recommendation

The company is at a pivotal stage with its lead asset, seralutinib, having completed enrollment for a Phase 3 PAH study with topline data expected in February 2026, and initiating another Phase 3 study for PH-ILD. The Chiesi collaboration provides strategic support and some funding. However, the significant increase in net losses, substantial cash burn, and explicit need for future capital raises introduce considerable financial risk and potential for dilution. Investors should hold to await the critical PROSERA data, which will be a major catalyst, while acknowledging the high-risk, high-reward profile inherent in late-stage biopharmaceutical development.

Keywords

Seralutinib, Pulmonary Hypertension, PAH, PH-ILD, Biopharmaceutical, Clinical Trials, Phase 3, Drug Development, Chiesi Collaboration, SEC Filing, Biotech